Publikation

Pulmonary Hypertension in Aortic and Mitral Valve Disease

Wissenschaftlicher Artikel/Review - 23.05.2018

Bereiche
PubMed
DOI

Zitation
Maeder M, Weber L, Buser M, Gerhard M, Haager P, Maisano F, Rickli H. Pulmonary Hypertension in Aortic and Mitral Valve Disease. Front Cardiovasc Med 2018; 5:40.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Front Cardiovasc Med 2018; 5
Veröffentlichungsdatum
23.05.2018
ISSN (Druck)
2297-055X
Seiten
40
Kurzbeschreibung/Zielsetzung

In patients with aortic and/or mitral valve disease the presence of pulmonary hypertension (PH) indicates a decompensated state of the disease with left ventricular and left atrial dysfunction and exhausted compensatory mechanism, i.e., a state of heart failure. Pulmonary hypertension in this context is the consequence of the backwards transmission of elevated left atrial pressure. In this form of PH, pulmonary vascular resistance is initially normal (isolated post-capillary PH). Depending on the extent and chronicity of left atrial pressure elevation additional pulmonary vascular remodeling may occur (combined pre- and post-capillary PH). Mechanical interventions for the correction of valve disease often but not always reduce pulmonary pressures. However, the reduction in pulmonary pressures is often modest, and persistent PH in these patients is common and a marker of poor prognosis. In the present review we discuss the pathophysiology and clinical impact of PH in patients with aortic and mitral valve disease, the comprehensive non-invasive and invasive diagnostic approach required to define treatment of PH, and recent insights from mechanistic studies, registries and randomized studies, and we provide an outlook regarding gaps in evidence, future clinical challenges, and research opportunities in this setting.